open access

Vol 15, No 5 (2019)
CASE REPORT
Published online: 2019-10-29
Get Citation

Uncontrolled reactivation of EBV infection in a 26-year-old woman

Agnieszka Wójcik, Anna Kiliszczyk, Beata Jagielska
DOI: 10.5603/OCP.2019.0030
·
Oncol Clin Pract 2019;15(5):269-274.

open access

Vol 15, No 5 (2019)
CASE REPORT
Published online: 2019-10-29

Abstract

This report describes the case of a 26-year-old woman, who was admitted to oncological centre with symptoms of lymphoma, but final diagnosis indicated CAEBV virus infection. The patient had never been treated for chronic diseases before, and lymphoma was suspected due to: clinical symptoms (neck lymphadenopathy, febrile conditions), and imaging and endoscopic ultrasound examinations (CT, EUS). During the examinations in the oncological centre, lymphoma diagnosis was turned down and CAEBV infection was recognised. Despite the treatment applied in accordance with global standards, the patient developed multi-organ failure, which led to her death.

Abstract

This report describes the case of a 26-year-old woman, who was admitted to oncological centre with symptoms of lymphoma, but final diagnosis indicated CAEBV virus infection. The patient had never been treated for chronic diseases before, and lymphoma was suspected due to: clinical symptoms (neck lymphadenopathy, febrile conditions), and imaging and endoscopic ultrasound examinations (CT, EUS). During the examinations in the oncological centre, lymphoma diagnosis was turned down and CAEBV infection was recognised. Despite the treatment applied in accordance with global standards, the patient developed multi-organ failure, which led to her death.

Get Citation

Keywords

CAEBV; lymphoma; alloASCT

About this article
Title

Uncontrolled reactivation of EBV infection in a 26-year-old woman

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 5 (2019)

Pages

269-274

Published online

2019-10-29

DOI

10.5603/OCP.2019.0030

Bibliographic record

Oncol Clin Pract 2019;15(5):269-274.

Keywords

CAEBV
lymphoma
alloASCT

Authors

Agnieszka Wójcik
Anna Kiliszczyk
Beata Jagielska

References (20)
  1. Charles T. Leach, Ciro V. Sumaya and Gail J. Harrison Feigin and Cherry's Textbook Pediatric Infectious Diseases, Chapter 159, 1992-2015.e12.
  2. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000; 343(7): 481–492.
  3. Szczeklik A. et al. Interna, MP, Kraków 2017, 1803–1823, 2383–2385.
  4. Krzakowski M, Potemski P, Warzocha K. at al., Onkologia kliniczna, t. III, Via Medica, Gdańsk. 2015: 1112–1159.
  5. Krzakowski M, Warzocha K (eds). Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013, Via Medica, Gdańsk 2013.
  6. Kawa K, Sawada A, Sato M, et al. Current Diagnosis and Treatment Strategy for Chronic Active Epstein-Barr Virus Infection. In: Hayat M. (eds) . Stem Cells and Cancer Stem Cells. Springer, Dordrecht 2012; 5.
  7. Kawa-Ha K, Franco E, Doi S, et al. Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. Lancet. 1987; 1(8525): 154.
  8. Virelizier JL, Lenoir G, Griscelli C. Persistent Epstein-Barr virus infection in a child with hypergammaglobulinaemia and immunoblastic proliferation associated with a selective defect in immune interferon secretion. Lancet. 1978; 2(8083): 231–234.
  9. Joo EJ, Ha YE, Jung DS, et al. An adult case of chronic active Epstein-Barr virus infection with interstitial pneumonitis. Korean J Intern Med. 2011; 26(4): 466–469.
  10. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol. 2005; 80(1): 64–69.
  11. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol. 2006; 16(4): 251–261.
  12. Kimura H. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001; 98(2): 280–286.
  13. Young Hyeh Ko, John K. C. Chan and Leticia Quintanilla-Martinez Hematopathology, Chapter 30, 565–598.e12.
  14. Ishihara S, Okada S, Wakiguchi H, et al. Clonal lymphoproliferation following chronic active Epstein-Barr virus infection and hypersensitivity to mosquito bites. American Journal of Hematology. 1997; 54(4): 276–281, doi: 10.1002/(sici)1096-8652(199704)54:4<276::aid-ajh3>3.0.co;2-s.
  15. Ishida Y, Yokota Y, Tauchi H, et al. Ganciclovir for chronic active Epstein-Barr virus infection. Lancet. 1993; 341(8844): 560–561.
  16. Majhail NS. Old and new cancers after hematopoietic-cell transplantation. Hematology Am Soc Hematol Educ Program. 2008: 142–149.
  17. Gross TG. Treatment for Epstein-Barr virus-associated PTLD. Herpes. 2009; 15(3): 64–67.
  18. Styczynski J, Reusser P, Einsele H, et al. Second European Conference on Infections in Leukemia. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009; 43(10): 757–770.
  19. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994; 330(17): 1185–1191.
  20. Kimura H, Morishima T, Kanegane H, et al. Japanese Association for Research on Epstein-Barr Virus and Related Diseases. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003; 187(4): 527–533.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl